AVENUE THERAPEUTICS, INC. (ATXI) — Current Report

AI-Powered SEC Filing Analysis

Latest Current Report Filed: 2026-02-23

Key Insights

Avenue Therapeutics obtained an exclusive, worldwide license from Duke University to develop and commercialize products, including ATX-04, for the treatment of lysosomal storage diseases.
The company plans to advance ATX-04 through a late-stage clinical development program, initially focused on treating Pompe disease as an adjunct to enzyme replacement therapy.
The license agreement includes customary development and commercialization obligations, as well as termination provisions, and will continue on a product-by-product and country-by-country basis as long as royalties are payable.

Want the newest filings?

This analysis covers the filing from 2026-02-23. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Current Report filings

Filed: 2025-12-31

Avenue Therapeutics held its 2025 annual meeting of stockholders, where shareholders approved the election of six directors and the ratification of KPMG LLP as the company's independent registered public accounting firm.
The company had 3,183,426 shares of common stock and 250,000 shares of Class A preferred stock outstanding and eligible to vote at the annual meeting.
The shareholders voted overwhelmingly in favor of all proposals, indicating strong support for the company's leadership and financial oversight.

Other reports for AVENUE THERAPEUTICS, INC.

Quarterly Report Insider Trading

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.